This article has a correction. Please see:

Abstract

Alzheimer's disease (AD) is now established as a progressive compromise not only of the neurons but also of the cerebral vasculature. Increasing evidence also indicates that cerebrovascular dysfunction may be a key or an aggravating pathogenic factor in AD, emphasizing the importance to properly control this deficit when aiming for effective therapy. Here, we report that simvastatin (3–6 months, 40 mg/kg/d) completely rescued cerebrovascular reactivity, basal endothelial nitric oxide synthesis, and activity-induced neurometabolic and neurovascular coupling in adult (6 months) and aged (12 months) transgenic mice overexpressing the Swedish and Indiana mutations of the human amyloid precursor protein (AD mice). Remarkably, simvastatin fully restored short- and long-term memory in adult, but not in aged AD mice. These beneficial effects occurred without any decreasing effect of simvastatin on brain amyloid-β (Aβ) levels or plaque load. However, in AD mice with recovered memory, protein levels of the learning- and memory-related immediate early genes c-Fos and Egr-1 were normalized or upregulated in hippocampal CA1 neurons, indicative of restored neuronal function. In contrast, the levels of phospholipase A2, enkephalin, PSD-95, synaptophysin, or glutamate NMDA receptor subunit type 2B were either unaltered in AD mice or unaffected by treatment. These findings disclose new sites of action for statins against Aβ-induced neuronal and cerebrovascular deficits that could be predictive of therapeutic benefit in AD patients. They further indicate that simvastatin and, possibly, other brain penetrant statins bear high therapeutic promise in early AD and in patients with vascular diseases who are at risk of developing AD.

Particularly, there is a relatively good consensus that statin therapy in early old age, but not in late age, is associated with a lower incidence of AD independent from the ApoE allele and, possibly more so, in patients with hypertension and cerebrovascular or coronary artery disease (Rockwood et al., 2002; Li et al., 2007, 2010; Cramer et al., 2008; Haag et al., 2009). It has been argued that the age-dependent benefits of statins in protecting against AD, which are reportedly dose dependent and related to statin pleiotropic effects rather than cholesterol-lowering effects, may be due to a critical time window when statins are able to prevent or delay neurodegenerative processes, which would not be achievable when neuronal damage has already occurred (Li et al., 2010; Butterfield, 2011).

We recently found that short, low-dose simvastatin (8 weeks, 20 mg/kg/d) partly restored cerebrovascular reactivity and brain hemodynamics, but failed to normalize memory in 12-month-old transgenic AD mice that overexpress the Swedish (K670N, M671L) and Indiana (V717F) mutations of human amyloid precursor protein (APP mice, line J20) (Tong et al., 2009). In the present study, we investigated whether cerebrovascular and memory deficits would be rescued by earlier and longer simvastatin therapy at a higher dose (40 mg/kg/d), and if such treatment would impact on key pathogenic markers at endpoint in adult (6-month-old, treated for 3 months) and aged (12-month-old, treated for 6 months) APP mice. The study demonstrates that simvastatin is fully effective against both cerebrovascular and memory deficits only if initiated early in the disease process. The data also establish that simvastatin beneficial effects are independent from the amyloid pathology, and that memory rescue occurs concurrently with normalization of proteins critical to synaptic function and memory processes. These findings establish that the therapeutic benefit of statins depends on a critical time window when it is still possible to revert the AD pathogenic process, hence favoring their use in early AD patients.

Materials and Methods

Animals.

Experiments were approved by the Animal Ethics Committee of the Montreal Neurological Institute (McGill University, Montréal, Québec, Canada) and complied with local and national regulations in accordance to the Canadian Council on Animal Care. Heterozygous transgenic C57BL/6 mice that express the APP carrying the human Swedish (K670N, M671L; APPSwe) and Indiana (V717F; APPInd) familial AD mutations directed by the PDGF β-chain promoter (APP mice, J20 line) (Mucke et al., 2000) and wild-type (WT) mice were used, with males and females in about equal number. APP J20 mice display early (2–4 months) cerebrovascular deficits (Tong et al., 2005) and increased levels of soluble Aβ species (Mucke et al., 2000) that precede the formation (5–6 months) of diffuse (Mucke et al., 2000) and dense-core Aβ plaques (Aucoin et al., 2005), including cerebral amyloid angiopathy. The latter, present in small arterial branches, is not detected in main arteries of the circle of Willis even at 12 months of age (Tong et al., 2009). Furthermore, APP J20 mice develop progressive cognitive deficits that are fully manifested by 6 months of age (Palop et al., 2003; deIpolyi et al., 2008).

Treatments.

Simvastatin (Enzo Life Sciences International) was activated by alkaline lysis, per the manufacturer's protocol, and was added to the drinking water such that mice received simvastatin at a dose of ∼40 mg/kg of body weight/d, which is similar to or lower than that used in other studies looking at systemic or central effects of simvastatin (Li et al., 2006; Lloyd et al., 2009; Yudoh and Karasawa, 2010). The animals were divided into two different age groups: adult (6 months old at endpoint, treated at 3 months of age for a period of 3 months) and aged (12 months old at endpoint, treated at 6 months for 6 months). Controls received the same drinking solution without simvastatin. Simvastatin was administered at 20 mg/kg/d for 3 d, increased to 30 mg/kg/d for 4 d, and then increased to 40 mg/kg/d for the rest of the treatment. Two treatment groups were formed for both adult and aged APP mice (7–30 mice/group); simvastatin-treated WT mice were included in only one cohort of each age group. Total cholesterol levels were measured in one of each age cohort with an Accutrend GC meter (Roche Diagnostic) and were similar in all groups as follows (in mmol/L): adult (n = 4/group): WT, 4.78 ± 0.04; WT treated, 4.68 ± 0.02; APP, 4.76 ± 0.04; APP treated, 4.81 ± 0.01; aged: WT (n = 11), 4.39 ± 0.05; WT treated (n = 9), 4.38 ± 0.04; APP (n = 9), 4.36 ± 0.07; APP treated (n = 8), 4.35 ± 0.04. Gain in body weight, measured in aged mice treated for the longest period (6 months), did not differ between groups, as follows (in grams): WT (n = 11), 1.89 ± 0.55; WT treated (n = 9), 1.55 ± 0.55; APP (n = 9), 2.13 ± 1.13; APP treated (n = 8), 0.52 ± 0.78.

Morris water maze.

Spatial memory was tested in the Morris water maze adapted for transgenic APP mice (deIpolyi et al., 2008), except for the first group of aged mice that was submitted to the classic 5-d-long Morris water maze, as detailed for the low-dose simvastatin treatment (Tong et al., 2009). For the adapted maze, mice first received a 3 d training session whereby they were required to swim to a visible platform in a room with visual wall cues. Then, after switching wall cues and platform location, the platform was submerged and training started for 5 consecutive days in which the mice had to find the hidden platform using the visuospatial cues. The probe trial (platform removed) was performed on day 9 for all groups, and a second probe trial was performed in one cohort of adult mice on day 17 (8 d after the first one). All parameters were recorded and analyzed (2020 Plus tracking system and Water 2020 software, HVS Image). All experiments started at the same time every day.

Fluorodeoxyglucose-positron emission tomography.

A subset of aged mice were scanned for cerebral glucose uptake (CGU) of [18F] fluorodeoxyglucose (FDG) in the somatosensory cortex following whisker stimulation, as detailed recently (Nicolakakis et al., 2008, 2011). Under isoflurane sedation (1–2% in medical air), mice received a bolus injection of 100–150 μCi (100 μl) of [18F]FDG into the tail vein and underwent 45 min of continuous unilateral whisker stimulation (8–10 Hz) followed by a 25 min positron emission tomography (PET) acquisition in an R4 microPET scanner (Siemens Preclinical Solutions; 15 min emission/10 min transmission scan using a 57Co point source). Physiological parameters (heart rate, respiration, and body temperature) were monitored (Biopac Systems), and stability was maintained throughout the procedure. Fasting glycemia was measured before scanning with a commercial glucometer (One Touch Ultra, LifeScan) using blood collected from the tail tip, and was comparable among all groups. Image processing and analysis were conducted using a dedicated imaging computational environment developed at the Montreal Neurological Institute (http://www.bic.mni.mcgill.ca/ServicesSoftware/MINC) (Pedersen et al., 2007). Images were acquired using a list mode and were reconstructed via maximum a posteriori probability algorithms (Kornblum et al., 2000) into dynamic (5 min) and static images. Dynamic images were used for assuring the absence of movement or artifacts during the acquisition. After quality control, static images followed a standard analytical procedure. Brain radioactivity standard uptake values (SUV) were obtained by dividing individually static tissue–radioactivity images by body mass and injected [18F]FDG dose. Spatial normalization (coregistration) to high-resolution anatomical MRI templates, acquired in separate groups of 10–11-month-old mice (WT, n = 5; APP, n = 4) with a 7 T Pharmascan system (Bruker BioSpin) (Nicolakakis et al., 2011), was conducted with a two-step semi-interactive method based on affine rigid body registration (six parameters) using the program Register (Montreal Neurological Institute). Volumes of interest on the maximally activated contralateral somatosensory cortex and corresponding area of the ipsilateral cortex were designed guided by SUV images and the MRI templates using a mouse brain atlas (Franklin and Paxinos, 1997). Volumes of interest were applied to the SUV images to obtain regional SUV values. The magnitude of activation was expressed as the ratio and the percentage change of [18F]FDG SUV values in the contralateral relative to the ipsilateral cortex.

Laser Doppler flowmetry.

Three days after the water maze, mice were used for laser Doppler flowmetry (LDF) measurements of CBF (Transonic Systems), as described previously (Tong et al., 2009). Mice were anesthetized with ketamine (85 mg/kg, i.m.; Bioniche) and xylazine (3 mg/kg, i.m.; Haver), and were placed in a stereotaxic frame on a heating blanket for maintaining stable body temperature (37°C). The bone over the barrel cortex (between 0 and 1 mm posterior, 3.5–4.5 mm lateral from bregma) (Ayata et al., 2004) was thinned to translucency for the LDF probe placement. Contralateral CBF was recorded and averaged (four to six stimulations every 30–40 s) before, during, and after unilateral whisker stimulation (20 s at 8–10 Hz). The probe was moved within the delineated area until a “hot spot” corresponding to the highest CBF increase was reliably found upon repeated stimulations. The hot spot was in the laterocaudal part of the barrel field, and virtually no CBF increases were obtained outside this area. Stimulus-evoked CBF was expressed as the percentage change relative to baseline. In a separate group of adult mice, the femoral artery was catheterized under isoflurane anesthesia (2 min, 5% in medical air for induction, 1.5–2% during surgery); anesthesia was then switched to ketamine/xylazine, and CBF, heart rate, and mean arterial blood pressure (MAP) were acquired before and during whisker stimulation (Powerlab, ADInstruments). Blood gases (pO2 and pCO2) and pH were measured at the end of the experiment (RapidLab 348, Bayer). Whisker stimulation or simvastatin did not alter any of these parameters, particularly MAP, as follows (in millimeters mercury, before/during stimulation): WT (n = 4), 72.2 ± 5.8/71.5 ± 5.7; WT treated (n = 3), 68.6 ± 13.3/68.6 ± 12.7; APP (n = 3), 82.6 ± 8.5/82.9 ± 8.9; and APP treated (n = 3), 65.2 ± 2.3/64.7 ± 2.2. The respective evoked CBF responses (percentage from baseline) were 19.0 ± 2.8, 15.7 ± 1.1, 9.4 ± 2.0, and 18.9 ± 1.2 (p < 0.05 for APP vs WT and APP treated).

Measurements of Aβ.

Levels of total (soluble and insoluble) Aβ1–40 and Aβ1–42 were measured by ELISA, which was performed as before (Tong et al., 2009) and as recommended by Invitrogen. Briefly, mouse hemibrains were weighted and homogenized in 5 m guanidine Tris HCl with a glass Teflon tissue grinder. Homogenates were diluted with a cold reaction buffer. The supernatants were used for analysis after centrifugation at 16,000 × g (20 min).

Data analysis.

Vascular responses (percentage change in diameter from basal or preconstricted tone) were plotted as a function of agonist concentration or duration of NOS inhibition. Concentration-dependent and maximal (EAmax) responses and the agonist concentration eliciting half the EAmax (EC50 value or pD2 ≤ log EC50) were used to compare agonist efficacy and potency, respectively. The number of and percentage area occupied (plaque load) by cortical and hippocampal thioflavine S-positive plaques were measured on digital pictures with the MetaMorph 6.1r3 program (Universal Imaging). For immunostaining, the numbers of positive c-Fos and Egr-1 nuclei were counted in 0.067 mm2 surface area on digital pictures (one picture from each section and three sections per mouse, four mice per group). The intensity of Egr-1-positive nuclei or cPLA2 staining in the hippocampus CA1 region was measured as total gray level using MetaMorph. For Western blot, bands were analyzed by densitometry using actin (mouse anti-β-actin; 1:1000; Sigma) to normalize for loading (Tong et al., 2005). LDF measurements of CBF were performed blind to the identity of the mice. For other in vivo experiments, the investigator was partially blinded (Morris water maze, mice being numbered and tested by gender) or only one of the investigators was totally blinded (FDG-PET) to the genotype. Data were expressed as mean ± SEM and compared by one-way ANOVA followed by Newman–Keuls post hoc multiple-comparison test or by Student's t test for two-group comparisons (GraphPad Prism 4). A p value <0.05 was taken as significant.

Results

Simvastatin restored cerebrovascular reactivity in APP mice

Cerebral arteries from adult and aged APP mice displayed impaired dilatations to ACh and CGRP at increasing and maximal agonist concentrations compared with WT controls (Fig. 1; Table 1). These deficits were not attributed to receptor desensitization since ACh and CGRP pD2 values did not differ between groups at any age (Table 1). The tonic production of the vasodilator NO, evaluated by inhibiting NOS activity with l-NNA, was also reduced in APP compared with WT arteries, the decrease being significant only in adult APP mice (Fig. 1, Table 1). In contrast to the low-dose short simvastatin treatment (20 mg/kg/d for 8 weeks) that failed to rescue ACh-induced dilatations in aged APP mice (Tong et al., 2009), a daily 40 mg/kg dose of simvastatin fully restored ACh- and CGRP-induced dilatations, and basal NO levels in adult or aged APP mice treated for 3 or 6 months (Fig. 1, Table 1). These findings suggest that dose and length of treatment are determinant for full recovery of cerebrovascular function.

Lack of NO bioavailability due to its trapping by NADPH oxidase-derived reactive oxygen species (ROS) (Iadecola et al., 1999; Tong et al., 2005; Park et al., 2008) and impaired cerebrovascular KATP channel function (Tong et al., 2009) have been identified as culprits of the altered dilatory responses. Consistently, in both adult and aged APP mice, O2− production was increased in the pial membrane and intracortical blood vessels, as were also the protein levels of the inducible antioxidant enzyme SOD2, a marker of increased oxidative stress (Wong and Goeddel, 1988) (Fig. 2). Simvastatin normalized both O2− production and SOD2 levels (Fig. 2), as previously reported for the low-dose simvastatin (Tong et al., 2009). In contrast, whereas the low-dose simvastatin had no benefit on KATP channel function in aged APP mice (Tong et al., 2009), the current treatment regimen completely restored the impaired dilatations to the selective KATP channel opener levcromakalim (16.7 ± 13.2% in APP vs 69.4 ± 2.4% of the induced tone in simvastatin-treated APP mice, p < 0.001) (Fig. 1). This may have allowed the recovery of CGRP-induced dilatations that are mediated by both NO and KATP channels (Kitazono et al., 1993). However, these channels were unimpaired in adult APP mice (Fig. 1) suggesting that, at that age, the dilatory dysfunctions likely resulted from ROS-induced sequestration of vasodilators or the impairment of other K+ channels, such as the calcium-dependent K+ (KCa) channels (Hong et al., 1996), which are also responsive to statin therapy, as shown in peripheral arteries (Miller et al., 2004).

Simvastatin preserved learning and memory in adult but not in aged APP mice

We found severe behavioral impairments in the Morris water maze at both ages, in agreement with previous studies in adult (Palop et al., 2003; deIpolyi et al., 2008) and aged (Nicolakakis et al., 2008; Tong et al., 2009) APP mice. APP mice overall had no difficulty learning to escape to the visible platform (days 1–3; Fig. 4). Importantly, time latencies to find the hidden platform were higher in APP mice compared with WT mice, indicating impaired learning at both ages (days 4–8; p < 0.01–0.001) (Fig. 4). Similarly, in the spatial memory component of the test, the time spent in the target quadrant or the number of crossings over the platform location was significantly reduced in adult and aged APP mice compared with their WT controls (probe trial, day 9; Fig. 4), despite no alteration in swim speed (data not shown). Simvastatin normalized learning and memory in adult APP mice (Fig. 4A), and this effect was both reproducible and persistent, as seen in the adult cohort tested in the probe trial on day 17 (Fig. 4B). However, as previously observed with the short low-dose simvastatin treatment in aged APP mice (Tong et al., 2009), simvastatin failed to rescue the learning and memory deficits of aged APP mice (Fig. 4C). Simvastatin had no effect on cognitive performance in either adult (Fig. 4B) or aged (data not shown) WT mice. Together, these findings show that pathological stage determines treatment efficacy and that timely therapeutic intervention is crucial for memory recovery.

Simvastatin did not reduce amyloidosis

To investigate whether simvastatin acted upon amyloidosis, a proposed but debatable role for statins (Tamboli et al., 2010), we measured soluble Aβ levels and Aβ plaque load in both age groups. Total soluble Aβ levels were detected in hippocampus of adult APP and in both cortex and hippocampus of aged APP mice by Western blot, but simvastatin exerted no reducing effect at either age (Fig. 5A). Similarly, levels of the different Aβ monomers or oligomers, including the 56 kDa assembly that has been linked to memory deficit (Lesné et al., 2006), were detected in adult APP mice with preserved memory using the anti-Aβ 6E10 antibody on a gradient gel, but no reducing effect of treatment was found in either cortex or hippocampus (data not shown). Simvastatin also had no significant effect on total Aβ1–40 and Aβ1–42 levels measured by ELISA in hemibrains of adult and aged APP mice (Fig. 5B). We then examined the Aβ deposits in cortex and hippocampus that, as expected, were smaller and less numerous in 6-month-old compared with 12-month-old APP mice (Fig. 5C). Simvastatin did not reduce Aβ plaque number or Aβ plaque load in cortex or hippocampus in treated APP mice at any age (Fig. 5C). The findings unequivocally demonstrate the ability of simvastatin to preserve memory in adult APP mice despite increased soluble Aβ species and ongoing plaque formation.

Simvastatin (SV) did not reduce amyloidosis in adult and aged APP mice. A, B, SV failed to reduce the levels of cortical (Co) and hippocampal (Hi) soluble Aβ oligomers (4 kDa) detected by Western blot (A), as well as those of total soluble Aβ1–40 and Aβ1–42 measured by ELISA in hemibrains (B). C, Similarly, the number of thioflavine S-positive plaques and the area they occupied in cortex or hippocampus (plaque load) did not differ between treated and nontreated adult or aged APP mice. Student's t test, n = 4–6 per group.

Simvastatin upregulated c-Fos and Egr-1 in the hippocampus CA1 region

Reduced levels of c-Fos in the hippocampus of APP mice have been suggested to contribute to cognitive deficits (Palop et al., 2003). Similarly, Egr-1 (Zif268), a member of the immediate–early gene family of transcription factors essential for long-term potentiation (LTP) and memory formation (Jones et al., 2001), was decreased in various models of APP mice either at baseline (Dickey et al., 2003) or following memory testing (Blanchard et al., 2008). We found that both adult and aged APP mice had lower baseline c-Fos and Egr-1 immunoreactivity in the hippocampus compared with their respective WT controls (Figs. 6, 7). Specifically, in the CA1 area of APP mice at both ages, there was a decrease in the number of c-Fos-positive nuclei (Fig. 6; difference not significant) and a highly significant decrease in the staining intensity and number of Egr-1-positive nuclei (−37.7 ± 6.2%, p < 0.05 and −50.9 ± 3.9%, p < 0.001 in adult and aged APP mice, respectively) (Fig. 7). In simvastatin-treated adult APP mice with restored memory, c-Fos and Egr-1 immunoreactivity was upregulated, and the number of immunostained nuclei or staining intensity compared with or exceeded that of WT controls (Figs. 6, 7). In contrast, in aged APP mice that failed to recover memory, simvastatin did not significantly improve c-Fos expression (−51 ± 12.8%, p < 0.05 vs WT controls) and had no effect on Egr-1 immunostaining (−47.5 ± 0.7%, p < 0.001) (Figs. 6, 7). Interestingly, simvastatin had a small promoting effect on the number of c-Fos nuclei in aged WT mice, normalizing them to the levels of adult WT mice (Fig. 6). These data demonstrate that simvastatin can rescue critical proteins underlying hippocampus-mediated memory processes in adult but not aged APP mice.

Simvastatin (SV) upregulated basal c-Fos expression in adult, but not aged, APP mice. Baseline immunostaining of c-Fos expression in the dorsal hippocampus indicated a smaller, albeit not significant, number of nuclei in adult and aged APP mice, as quantified in the CA1 area (delineated by arrows). In adult APP mice, SV treatment upregulated c-Fos expression, the number of c-Fos nuclei being higher than in WT mice. Whereas such an enhancing effect did not occur in aged APP mice, SV normalized the number of c-Fos nuclei in aged WT mice to that seen in adult WT mice. *p < 0.05, **p < 0.01. ANOVA and Newman–Keuls test, n = 9–13 per group (adult) and n = 4 per group (aged). Scale bar, 50 μm.

Simvastatin (SV) normalized basal Egr-1 protein levels in adult, but not aged, APP mice. Egr-1 immunostaining in the dorsal hippocampus revealed a drastic reduction in the number of nuclei and staining intensity in the CA1 area of both adult and aged APP mice (delineated by arrows in left panels and magnified in right panels). In adult APP mice, SV normalized the number of Egr-1-positive nuclei and increased staining intensity (total gray value) to levels higher than in WT mice treated or nontreated with SV. *p < 0.05; **p < 0.01; ***p < 0.001. ANOVA and Newman–Keuls test, n = 4 per group. Scale bar, 50 μm.

Simvastatin did not act upon other synaptic or memory-related proteins

Memory deficit in APP mice has also been imputed to increased levels of ENK (Meilandt et al., 2008) and PLA2 (Sanchez-Mejia et al., 2008), and to decreases in synaptic proteins and NMDA receptor subunits or their downstream signaling pathways (Yamin, 2009). We confirmed upregulation of ENK immunoreactivity in the dentate gyrus and mossy fiber area, and of PLA2 in the stratum radiatum of the CA1 area in the hippocampus of both adult and aged APP mice (Fig. 8). These increased protein levels, however, were not normalized by simvastatin at any age and despite memory recovery in the adult cohorts (Fig. 8). Furthermore, we found no change in synaptic markers PSD-95, synaptophysin, or the NMDA receptor subunit NR2B in synaptosomal P2 fractions from cortex and hippocampus in adult and aged APP mice compared with WT controls (Fig. 9). These findings agree with unchanged levels of presynaptic and postsynaptic markers in 6- or 18-month-old APPSwe (Gu et al., 2009) or APP/PS1 (Dickey et al., 2003) mice, but not with those reporting decreased density of synaptophysin-immunoreactive terminals in APPInd mice between 2 and 28 months of age (Hsia et al., 1999) or aged APPSwe,Ind mice (Mucke et al., 2000). Simvastatin did not affect these proteins in adult APP or WT mice (Fig. 9).

Synaptic markers were unaltered in adult and aged APP mice and by simvastatin (SV). Representative Western blots for synaptic density proteins PSD-95, synaptophysin (SYN), and the NR2B subunit of NMDA receptors measured in the synaptosomal (P2) fraction prepared from cortex and hippocampus from WT, APP, and APP mice treated with SV. No change was observed between APP and WT mice at any age, and SV did not affect these proteins in adult APP mice. n = 4–5 per group.

Discussion

Using cognitive and cerebrovascular measures as indexes of clinical outcome in APP mice, we report that simvastatin showed full efficacy in restoring cerebrovascular function in adult and aged APP mice, but that therapeutic benefit on learning and memory was restricted to adult mice. We found that recovery of vasodilatory capacity concurred with restoration of NO bioavailability and KATP channel function, and that memory recovered concomitantly with upregulation of baseline c-Fos- and Egr-1-expressing cells in the CA1 area of the hippocampus, notwithstanding a progressing Aβ pathology. These findings demonstrate clear benefits for simvastatin on two main landmarks of AD pathology, and on key proteins required for hippocampal synaptic function through which memory could be preserved.

We performed all reactivity studies on proximal PCA branches to avoid the rare, albeit likely, presence of Aβ deposits in most distal segments of the artery in aged animals (Tong et al., 2009), as these could further impair dilatory capacity through mechanical damage (Park et al., 2008, Han et al., 2008). Hence, the cerebrovascular deficits reported here are strictly imputed to soluble Aβ species that impair cerebrovascular function essentially through increased production of NADPH oxidase-derived ROS (Iadecola et al., 1999; Tong et al., 2005, 2009; Park et al., 2008, 2011). In this respect, the antioxidant capacity of the high-dose simvastatin was evidenced in the cerebral vasculature of APP mice at both ages, but was particularly striking in aged mice with prominent oxidative stress. Indeed, simvastatin reduced O2− production and normalized the levels of the antioxidant SOD2. This likely resulted in sufficient NO bioavailability to restore basal vessel tone and ACh-mediated dilatations that necessitate the synthesis of additional endothelial NOS-derived dilators (Drouin et al., 2007). The functional recovery achieved with the high-dose, as opposed to the low-dose, simvastatin that failed to rescue the ACh dilatation in aged mice (Tong et al., 2009) was analogous to that obtained with pharmacologic or genetic ROS-countering strategies targeting the production (Kitazono et al., 1993; López et al., 2008) or elimination of O2− with SOD (Iadecola et al., 1999; Miller et al., 2004; Tong et al., 2009), or with the SOD mimetic Tempol (Nicolakakis et al., 2008). Hence, the greater antioxidant properties of a higher-dose simvastatin likely accounted for normalized KATP channel-mediated dilatation in aged APP mice, since O2− can inhibit BK, KATP, and inwardly rectifying potassium channels in cerebral arteries, and this impairment can be restored by topical SOD application (Erdös et al., 2004). Although not measured in the current study, myogenic tone of cerebral arteries is also highly sensitive to ROS (Maneen and Cipolla, 2007), and simvastatin may have acted at this level. Yet, an activating effect of simvastatin on brain endothelial NOS activity (Sugawara et al., 2008) and a direct relaxant effect through KCa channel activation, as reported for rosuvastatin in peripheral arteries (López et al., 2008), could also contribute to the functional recovery.

Simvastatin antioxidant and anti-inflammatory properties may be credited for the normalized stimulus-induced increases in glucose metabolism and CBF during whisker stimulation. Both responses require astrocytes as intermediaries either for glucose uptake (Chuquet et al., 2010) or calcium signaling and release of vasodilatory mediators (Koehler et al., 2009). Simvastatin attenuated astrocyte activation in the cortex where the CGU and CBF responses were recorded, and reduced the number of ROS-producing NADPH/p22phox subunit-positive glial cells (Tong et al., 2009). Similar rescue of neurometabolic and neurovascular coupling responses was observed in elderly APP mice following pharmacologic (Nicolakakis et al., 2008) or genetic (Park et al., 2008) anti-inflammatory or antioxidant therapy. Together, these findings indicate that simvastatin counters Aβ-induced deleterious effects by targeting inflammatory and oxidative reactions. With the latter being detrimental to astrocytes, neurons, and the brain vasculature (Yang et al., 2010), our data identify multiple cell types where simvastatin can act to rescue brain energetics and hemodynamics. Whereas such benefits were not exclusive to simvastatin, as pure antioxidants or other drugs with pleiotropic effects, such as peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists, were as effective (Nicolakakis et al., 2008), they clearly point to the high efficacy of simvastatin in rescuing changes in brain metabolism and perfusion induced by neuronal activity.

On the contrary, one benefit unique to simvastatin, and not reproduced by antioxidants or PPAR-γ agonists, was the restoration of learning and memory, and most strikingly of long-term memory, in adult APP mice. Behavioral recovery occurred with no reduction in brain levels of soluble Aβ or Aβ plaque load, in agreement with a previous study that found cognitive improvement in Tg2576 APP mice independently from decreased amyloidosis (Li et al., 2006). These findings also match exquisitely well with those in asymptomatic middle-aged adults at risk for AD, in whom working memory improvements occurred without changes in CSF Aβ42 (Carlsson et al., 2008). What is more, we found that simvastatin-treated adult APP mice with restored memory displayed upregulated c-Fos and Egr-1 protein levels in the CA1 region of the hippocampus when tested up to 2 weeks after the last probe trial, demonstrating an effect of simvastatin on basal levels of these memory-related proteins or on hippocampal neuron function. Interestingly, a positive correlation between spatial learning and constitutive Egr-1 mRNA expression, selectively in CA1 pyramidal neurons, has been documented (Yau et al., 1996), and increased basal Egr-1 expression induced by transgenesis was reported to enhance long-term memory (Baumgärtel et al., 2008). Several studies have also related increased c-Fos or Egr-1 expression to various forms of learning and memory, particularly long-term memory (Jones et al., 2001; Davis et al., 2003; Fleischmann et al., 2003).

Deletion of the cAMP response element-binding protein (CREB), which is upstream of c-Fos and Egr-1, resulted in learning and long-term memory deficits (Pittenger et al., 2002). Activation of CREB has been associated with the MAPK/ERK and the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways, both implicated in LTP and memory processes (Davis et al., 2000; Jones et al., 2001; Bozon et al., 2003; Mizuno et al., 2003). Most relevant to the present findings, these pathways are activated by simvastatin (Li et al., 2006; Beretta et al., 2011), and a body of evidence has recently accumulated for a role of the PI3K pathway in the positive effect of simvastatin on memory. Particularly, chronic simvastatin treatment increased brain levels of total and phosphorylated Akt (P-Akt) in WT mice with enhanced learning and memory performance (Li et al., 2006). In hippocampal slices from WT mice, prolonged simvastatin treatment increased P-Akt in the CA1 area concomitantly with improved LTP at CA3–CA1 synapses, an effect suppressed by inhibition of Akt phosphorylation (Mans et al., 2010). Together, these findings support that simvastatin rescued memory in adult APP mice by restoring the ability of hippocampal CA1 neurons to respond to synaptic input, possibly by restoring the PI3K/Akt → P-CREB → Egr-1/c-Fos signaling cascade that is crucial for spatial memory. This would also agree with the simvastatin-mediated activation of the PI3K/Akt pathway associated with neuroprotection after hypoxic-ischemic brain damage (Carloni et al., 2009). Simvastatin also improved CBF and behavioral outcome, and decreased hippocampal degeneration after brain injury (Wang et al., 2007; Wu et al., 2008), and was the most protective statin against kainate-induced excitotoxicity and memory impairment (Ramirez et al., 2011).

We conclude that the remarkable benefit of simvastatin on both cerebrovascular and neuronal deficits in adult AD mice results from its combined pleiotropic properties as a cerebrovascular antioxidant and neuronal regulator of memory-linked c-Fos and Egr-1 proteins. The results in aged mice further demonstrate that full recovery of cerebrovascular function does not necessarily translate into normalized cognitive performance, suggesting that simvastatin efficacy on neuronal pathways is protective rather than restorative even though there might be a time window where these two mechanisms overlap. Since the kind of statins, onset of treatment, and clinical status of the patients may be critical for efficacy in AD (Wolozin et al., 2000; Haag et al., 2009), our results of an age-related benefit for simvastatin on memory pathways establish simvastatin as a highly valuable statin to consider for the treatment of early AD and of patients at risk for AD due to vascular diseases.

Footnotes

This work was supported by the Canadian Institutes of Health Research Grant MOP-84275 (to E.H.) and a fellowship from the Heart & Stroke Foundation of Canada/Canadian Stroke Network (to C.L.). We thank Dr. L. Mucke (Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, San Francisco, CA) and the J. David Gladstone Institutes for the APP transgenic mouse breeders. We are indebted to Ms. P. Fernandes [Montreal Neurological Institute (MNI), Montréal, Québec, Canada] for the laser Doppler flowmetry experiments; J. Cakiroglu and Dr. B. Bedell (Small Animal Imaging Laboratory, MNI) for the MRI templates; Dr. P. Rosa-Neto (Brain Imaging Centre, MNI) for his help with the PET data analysis; Dr. N. Nicolakakis (MNI) for reviewing the manuscript; and P. Papadopoulos (MNI) for help with some treatments.

(2008) Participation of K+ channels in the endothelium-dependent and endothelium-independent components of the relaxant effect of rosuvastatin in rat aortic rings. J Cardiovasc Pharmacol Ther13:207–213.

(2008) Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma25:130–139.